Gilead Delayed Safer HIV Drug to Extend Monopoly Profits, Advocates Allege - GV Wire - Explore. Explain. Expose
Connect with us

Aggregation

Gilead Delayed Safer HIV Drug to Extend Monopoly Profits, Advocates Allege

Published

on

Photo of Gilead pills
Share with friends

Subscription

In 2005, Gilead Sciences notified federal regulators that it was suspending development of a potentially safer, more potent HIV-fighting drug than the one on the market. The company did not restart its Food and Drug Administration application until 2010. Now the five-year delay of a promising drug is at the core of accusations by advocates that Gilead improperly exploited the patent system at the expense of patient health.
An HIV-prevention group called PrEP4All Collaboration filed a petition Wednesday with the U.S. Patent and Trademark Office contending Gilead knew its new, improved drug — approved in 2015 and now part of Gilead’s combination therapies Genvoya and Descovy — was safer. But it alleged Gilead postponed development so it could continue to gain monopoly profits from its older combination HIV drugs, including Viread and Truvada, for a longer period,before those drugs went off patent and faced generic competition.

Read More →

Continue Reading
Advertisement GVwire